ATRX and central nervous system cancer: To further validate the fact that PARP inhibitor enhanced TMZ sensitivity by suppressing ATRX-mediated PARP1 stabilization in TMZ resistant gliomas, we established xenograft mouse models and treated them with TMZ and (or) olaparib.